AR015422A1 - BIOSYNTHESIS INHIBITORS OF PROSTAGLANDINA ENDOPEROXIDO H SINTASA, A METHOD FOR OBTAINING IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT - Google Patents

BIOSYNTHESIS INHIBITORS OF PROSTAGLANDINA ENDOPEROXIDO H SINTASA, A METHOD FOR OBTAINING IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT

Info

Publication number
AR015422A1
AR015422A1 ARP980104193A ARP980104193A AR015422A1 AR 015422 A1 AR015422 A1 AR 015422A1 AR P980104193 A ARP980104193 A AR P980104193A AR P980104193 A ARP980104193 A AR P980104193A AR 015422 A1 AR015422 A1 AR 015422A1
Authority
AR
Argentina
Prior art keywords
heterocyclic
alkyl
group
arylalkyl
cycloalkyl
Prior art date
Application number
ARP980104193A
Other languages
Spanish (es)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR015422A1 publication Critical patent/AR015422A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Inhibidores de biosíntesis de prostaglandina endoperoxido H sintasa, que comprende un compuesto que tiene la formula (I) en la cual X está seleccionado delgrupo que consiste en O, S, NR4, N-ORa, y N-NRbRc, donde R4 está seleccionado del grupo que consiste en alquilo, alquenilo, cicloalquilo, cicloalquenilo,cicloalquilalquilo, cicloalquenilalquilo, arilo heterocíclico, alquilo heterocíclico y arilalquilo; y Ra, Rb y Rc, están independientemente seleccionados delgrupo que consiste en alquilo, cicloalquilo, cicloalquilalquilo, arilo y arilalquilo; R está seleccionado del grupo que consiste en hidrogeno, alquilo,alquenilo, alquinilo, alquilcarbonilalquilo, alquilsulfonilalquilo, alquilsulfonilarilalquilo, alcoxi, alcoxialquilo, carboxi, carboxialquilo, cianoalquilo,haloalquilo, haloalquenilo, haloalquinilo, hidroxialquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilo, cicloalquenilalquilo, arilo, arilalquilo,arilalquenilo, arilalquinilo, arilalcoxi, arihaloalquilo, arilhidroxialquilo,ariloxi, ariloxihidroxialquilo, ariloxihaloalquilo, arilcarbonilalquilo,haloalcoxihidroxialquilo, heterocíclico, alquilo heterocíclico, alcoxi heterocíclico, oxi heterocíclico, -C(O)R5, -(CH2)nC(O)R5, -R6-R7, -(CH2)nCH(OH)R5,-(CH2)nCH(ORd)R5, -(CH2)nC(NORd)R5, -(CH2)nC(NRd)R5, -(CH2)nCH(NORd)R5, -(CH2)nCH(NRdRe)R5, -CH2)nC:::C-R7, -(CH2)n[CH(CX3)]m-(CH2)n-CX3, -(CH2)n(CX2)m-(CH2)n-CX3,-(CH2)n[CH(CX3)]m-(CH2)n-R8, (CH2)n(CX2)m-(CH2)nR8, -(CH2)n(CHX)m-(CH2)m-(CH2)n-CX3, -(CH2)n(CHX)m-(CH2)n-R8, y-(CH2)n-R20, donde R5 esseleccionado del grupo que consiste en alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, arilalquilo, haloalquilo, haloalquenilo,haloalquinilo, heterocíclico yalquilo heterocíclico; donde R6 es alquileno o alquenileno, o alquileno halo sustituido o alquenileno halo-sustituido; R7 y R8están independientemente seleccionados del grupo que consiste en hidrogeno, alquilo, alquenilo, alquinilo, haloalquilo, cicloalquilo, cicloalquenilo, arilo,arilalquilo, heterocíclico, y alquilo heterocíclico; R20 está seleccionado del grupo que consiste en alquilo, alquenilo, haloalquilo, cicloalquilo,Biosynthesis inhibitors of prostaglandin endoperoxide H synthase, comprising a compound having the formula (I) in which X is selected from the group consisting of O, S, NR4, N-ORa, and N-NRbRc, where R4 is selected from group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenyl alkyl, heterocyclic aryl, heterocyclic alkyl and arylalkyl; and Ra, Rb and Rc, are independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl and arylalkyl; R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkylsulfonylarylalkyl, alkoxy, alkoxyalkyl, carboxy, carboxyalkyl, cyanoalkyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, arylalkyl, arylalkenyl, arylalkyl, arylalkoxy, arihaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhydroxyalkyl, aryloxyhaloalkyl, arylcarbonylalkyl, haloalkoxyhydroxyalkyl, heterocyclic, heterocyclic, heterocyclic, Ci-C2-alkyl, heterocyclic, R-C6-alkocyclic, heterocyclic (C) -alcyl, heterocyclic, Ci-C2-alkyl -R6-R7, - (CH2) nCH (OH) R5, - (CH2) nCH (ORd) R5, - (CH2) nC (NORd) R5, - (CH2) nC (NRd) R5, - (CH2) nCH (NORd) R5, - (CH2) nCH (NRdRe) R5, -CH2) nC ::: C-R7, - (CH2) n [CH (CX3)] m- (CH2) n-CX3, - (CH2) n (CX2) m- (CH2) n-CX3, - (CH2) n [CH (CX3)] m- (CH2) n-R8, (CH2) n (CX2) m- (CH2) nR8, - (CH2 ) n (CHX) m- (CH2) m- (CH2) n-CX3, - (CH2) n (CHX) m- (CH2) n-R8, and- (CH2) n-R20, where R5 is selected from the group that which consists of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclic and heterocyclic alkyl; where R 6 is alkylene or alkenylene, or halo substituted alkylene or halo substituted alkenylene; R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl; R20 is selected from the group consisting of alkyl, alkenyl, haloalkyl, cycloalkyl,

ARP980104193A 1997-08-22 1998-08-24 BIOSYNTHESIS INHIBITORS OF PROSTAGLANDINA ENDOPEROXIDO H SINTASA, A METHOD FOR OBTAINING IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT AR015422A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91702397A 1997-08-22 1997-08-22
US12957098A 1998-08-05 1998-08-05

Publications (1)

Publication Number Publication Date
AR015422A1 true AR015422A1 (en) 2001-05-02

Family

ID=26827711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104193A AR015422A1 (en) 1997-08-22 1998-08-24 BIOSYNTHESIS INHIBITORS OF PROSTAGLANDINA ENDOPEROXIDO H SINTASA, A METHOD FOR OBTAINING IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT

Country Status (14)

Country Link
JP (1) JP2003516925A (en)
KR (1) KR100675028B1 (en)
CN (1) CN1167687C (en)
AR (1) AR015422A1 (en)
AU (1) AU741317B2 (en)
BG (1) BG64675B1 (en)
CZ (1) CZ300847B6 (en)
HU (1) HUP0400909A3 (en)
IL (1) IL133552A (en)
NO (1) NO315423B1 (en)
NZ (1) NZ501808A (en)
PL (1) PL194175B1 (en)
SK (1) SK286972B6 (en)
TR (1) TR200000478T2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279026C (en) * 1998-10-27 2006-10-11 艾博特公司 Prostaglandin endoperoxide H synthase biosynthesis inhibitors
FR2969606B1 (en) * 2010-12-22 2013-01-11 Pf Medicament DERIVATIVES OF DIARYLPYRIDAZINONES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS
CN107334767B (en) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 A kind of application of pyridazinone compound in oncotherapy
JP7147444B2 (en) * 2018-10-03 2022-10-05 株式会社島津製作所 Sample injection device and sample injection system
CN114560814B (en) * 2022-03-02 2023-10-20 天津理工大学 Synthesis method of substituted 2, 3-naphthyridine ketone compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
JPS57501328A (en) * 1980-08-07 1982-07-29
US4404203A (en) * 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
IL115889A0 (en) * 1994-11-14 1996-01-31 Rohm & Haas Pyridazinones and their use as fungicides
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
AU6269496A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations
CA2283399C (en) * 1997-03-14 2006-02-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2

Also Published As

Publication number Publication date
SK2312000A3 (en) 2001-02-12
BG64675B1 (en) 2005-11-30
NO20000863L (en) 2000-02-22
SK286972B6 (en) 2009-08-06
KR100675028B1 (en) 2007-01-29
AU8697698A (en) 1999-03-16
TR200000478T2 (en) 2002-04-22
IL133552A0 (en) 2001-04-30
KR20010023196A (en) 2001-03-26
CN1277605A (en) 2000-12-20
NO315423B1 (en) 2003-09-01
AU741317B2 (en) 2001-11-29
BG104241A (en) 2000-10-31
CZ300847B6 (en) 2009-08-26
CN1167687C (en) 2004-09-22
HUP0400909A3 (en) 2004-10-28
HUP0400909A2 (en) 2004-07-28
NZ501808A (en) 2002-12-20
CZ2000446A3 (en) 2000-05-17
JP2003516925A (en) 2003-05-20
PL355418A1 (en) 2004-04-19
IL133552A (en) 2005-12-18
NO20000863D0 (en) 2000-02-22
PL194175B1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
CO4970740A1 (en) PIRIDAZINONE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE H SYNTHASA BIOSYNTHESIS
DE3683403D1 (en) IMIDAZOHETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT.
BG101917A (en) New taxoids, their preparation and pharmaceutical compositions containing them
HUP0200210A2 (en) Camptothecin derivatives having antitumor activity, process for their preparation and pharmaceutical compositions containing them
AR003962A1 (en) DIHIDRODIBENZO / B, F / AZEPINES USEFUL IN THE TREATMENT OF SOME DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM, METHOD FOR PREPARING SUCH COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS, AND THEIR USES
EP1070710A3 (en) Dithiolan derivatives, their preparation and their therapeutic effect
ES2121441T3 (en) NEW DERIVATIVES OF 3,5-DIOXO - (2H, 4H) - 1,2,4 - TRIAZINE, ITS PREPARATION AND APPLICATION AS A PHARMACY
MX9304571A (en) FANILIC COMPOUNDS LINKED TO AN ARYLL OR HETEROARILO THROUGH AN ALIPHATIC RADICAL OR A HETEROGENEOUS ATOM CONTAINING A LINK GROUP.
ATE250622T1 (en) 4'-C-ETHYNYL-PYRIMIDINES NUCLEOSIDES
ATE275562T1 (en) NEW FORM OF IRBESARTAN, METHOD FOR OBTAINING THIS FORM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
ES2097142T3 (en) DERIVED FROM INDOL, ITS PREPARATION AND THE CONTAINING MEDICINE INTENDED FOR THE PREVENTION AND TREATMENT OF NEPHRITIS.
ATE25977T1 (en) FURANONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE.
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
AR015422A1 (en) BIOSYNTHESIS INHIBITORS OF PROSTAGLANDINA ENDOPEROXIDO H SINTASA, A METHOD FOR OBTAINING IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT
EA200000948A1 (en) NEW POLYCYCLIC AZAINDOLS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2034909A6 (en) Inhibition of withdrawal syndrome.
HUP0102522A2 (en) 3',3'-n-bis-substituted macrolide lhrh antagonists and their use, process for their preparation and pharmaceutical compositions comprising them
HUP0402585A2 (en) Novel benzothiazine and benzothiadiazine derivatives, method for preparing same, their use and pharmaceutical compositions containing same
EP0240978A3 (en) Ether compounds, process for their preparation, compositions containing the same and use thereof
HUP0302408A2 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
HUP0002291A2 (en) Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha1-blocking action
IL90043A0 (en) Sulfonanilides,their preparation and pharmaceutical compositions containing them
WO1999007718A3 (en) Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same
AR004406A1 (en) NEW TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
IL117461A0 (en) New derivatives of beta-methoxy acrylic acid their preparation process and their use as pesticides

Legal Events

Date Code Title Description
FG Grant, registration